- $691.76m
- $481.58m
- $404.32m
- 79
- 45
- 65
- 67
2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 299 | 355 | 391 | 401 | 404 |
Cost of Revenue | |||||
Gross Profit | 222 | 268 | 292 | 297 | 317 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 422 | 449 | 481 | 466 | 411 |
Operating Profit | -123 | -94.3 | -90 | -64.8 | -6.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -120 | -94.6 | -92 | -63.9 | -0.338 |
Provision for Income Taxes | |||||
Net Income After Taxes | -122 | -94.7 | -93.3 | -65.9 | -2.63 |
Net Income Before Extraordinary Items | |||||
Net Income | -122 | -94.7 | -93.3 | -65.9 | -2.63 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -122 | -94.7 | -93.3 | -65.9 | -2.63 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.09 | -0.791 | -0.73 | -0.526 | -0.021 |